HLA-G5 is secreted by erythroblasts in all hematopoietic organs, suggesting a role for this protein in erythropoiesis. To examine this, we analyzed whether HLA-G5 affects the proliferation of UT7/EPO and HEL erythroleukemia cells and characterized the mechanism by which HLA-G5 influences erythropoietin receptor (EPOR) signaling. We show that HLA-G5 inhibits the proliferation of UT7/EPO cells, the EPOR signaling of which is similar to that of normal erythroid progenitors. HLA-G5-mediated inhibition was associated with reduced phosphorylation of JAK2 kinase and that of the downstream signaling proteins STAT-5 and STAT-3. Involvement of JAK2 in erythroid cell proliferation has been highlighted by the role of JAK2 V617F mutation in polycythemia vera (PV), a myeloproliferative disorder characterized by erythroid lineage overproduction. We demonstrate that HLA-G5 downregulates EPOR constitutive signaling of JAK2 V617F-expressing HEL cells, leading to inhibition of cell proliferation through G1 cell cycle arrest. Combination of HLA-G5 with JAK inhibitor I further decreases HEL cell growth. Clinical relevance is provided by analysis of PV patients who carry JAK2 V617F mutation, showing that HLA-G5 inhibits the formation of erythropoietin-independent erythroid colonies. Such HLA-G5-mediated inhibition constitutes a new parameter to be considered in the design of future approaches aimed at treating JAK2 V617F-positive myeloproliferative disorders.
Introduction
HLA-G is a non-classical HLA class I molecule with restricted tissue distribution and its immunotolerogenic properties have been widely demonstrated. 1 To date, seven HLA-G protein isoforms have been described: four are membrane-bound (HLA-G1 to -G4) and three are soluble (HLA-G5 to -G7). We recently described a novel site of HLA-G expression corresponding to erythroid cells. 2 We showed that HLA-G5 soluble isoform is a marker of erythropoietic lineage in all hematopoietic organs throughout human life. This specific expression suggests a non-immunological role for HLA-G in erythropoiesis.
Erythropoietin (EPO) is a crucial regulator of erythropoiesis. 3 Its binding confers a conformational change to the erythropoietin receptor (EPOR), which activates the pre-bound, cytoplasmic JAK2 kinase. In turn, JAK2 phosphorylates EPOR, which leads to activation of downstream signaling proteins, including the signal transducer activator of transcription 5 (STAT-5), assuming survival, proliferation and differentiation of erythroid cells. 4 Recently, an acquired activating mutation in the gene encoding JAK2 (JAK2 V617F) was identified in nearly all patients with the myeloproliferative disorder polycythemia vera (PV) and in half of those with essential thrombocythemia and idiopathic myelofibrosis. [5] [6] [7] [8] The JAK2 V617F mutation confers constitutive activity to the kinase with enhanced downstream signaling. [6] [7] [8] [9] This deregulated JAK2 activity has been associated with overproduction of erythroid cell lineage and with EPO-independent growth of erythroid progenitors in PV disorder.
To analyze whether HLA-G5 plays a role in erythropoiesis, we evaluated the proliferation of both normal JAK2-and JAK2 V617F-expressing erythroid cell lines and defined the mechanisms by which HLA-G5 modulates the EPOR signal-transduction pathways in both cell lines. Finally, we investigated the effect of HLA-G5 on the formation of EPO-independent erythroid colonies from PV patients.
Materials and methods

Samples from patients
Blood or bone marrow samples from PV patients were collected at the time of diagnosis before treatment. All patients fulfilled the WHO diagnostic criteria for PV. 10 Informed consent was obtained from all patients according to the Helsinki declaration, and the study was approved by the local ethics committee.
HLA-G5 treatment
Recombinant HLA-G5 was used either free or aggregated onto beads, while plasma HLA-G5 was always used after being captured by beads. 11 Briefly, microbeads (Ademtech, Pessac, France) were incubated first with the 5A6G7 antibody to HLA-G5 (Exbio, Prague, Czech Republic) 2 and then with either rHLA-G5-containing medium or HLA-G5-containing plasma samples.
Clonogenic assays
Mononuclear cells from peripheral blood (patients nos. 1, 2, 4-8) or bone marrow (patient no. 3) of PV patients were plated in duplicate wells with or without rHLA-G5 at 5 Â 10 5 ml -1 for patients nos. 1, 2, 5 and 6, at 2 Â 10 5 ml -1 for patient no. 4, at 1 Â 10 5 ml -1 for patient nos. 7 and 8 and at 5 Â 10 4 ml -1 for patient no. 3 in Methocult H4534 (Stem cell Technologies, Vancouver, Canada). For patient no. 7, cells were also cultured in the presence of 0.1 IU EPO ml
À1
, and for patient no. 8, culture was done only in the presence of such an EPO concentration. Erythroid colonies were scored at day 14 by standard morphological criteria using an inverted microscope.
Immunoprecipitation and western blotting
UT-7/EPO cells were deprived of EPO overnight. 1 Â 10 7 UT-7/ EPO or HEL cells were incubated in the presence of HLA-G5 or JAK inhibitor I (Calbiochem, Darmstadt, Germany) for 2-4 h. After treatment of UT-7/EPO cells with HLA-G5, EPOR was activated by the addition of 10 IU EPO for 10 min. Total protein extracts were incubated with rabbit antibody to JAK2 or to phosphotyrosine (clone 4G10) (Upstate, Lake Placid, NY, USA) and then with protein G-Sepharose (Sigma, St Louis, MO, USA) or A/G Plus-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA). When total protein extracts were subjected to SDSpolyacrylamide gel electrophoresis and before phosphotyrosine protein immunoprecipitation, total proteins were quantified using the BCA protein assay kit (Pierce, Rockford, IL, USA). The proteins were then resolved on 8% SDS-polyacrylamide gel electrophoresis and subjected to immunoblotting using rabbit antibody to phospho-JAK2 (Tyr1007/1008) or to phospho-STAT-5 (Tyr694) or to phospho-STAT-3 (Tyr705) (Cell Signaling, Danvers, MA, USA). The same membrane was subsequently probed with the rabbit antibody to JAK2 or to tubulin (Sigma). Quantification of blotted proteins was made by densitometric analysis of scanned films using Fluorchem software (AlphaInnotech, CA, USA). Western blotting of plasma HLA-G5-beads was done using 12% SDS-polyacrylamide gel electrophoresis and immunoblotting, using the 4H84 antibody to HLA-G. 12 Cell proliferation assays UT7/EPO cells were plated in triplicate wells at 5 Â 10 3 cells 100 ml -1 medium containing 0.0625 IU. EPO and increasing concentrations of either HLA-G5-beads or beads alone were used as negative control. The same procedures were used for HEL cells except that culture was done without EPO. After incubation for different time periods, cell viability was evaluated by Trypan blue exclusion. In parallel, plates were pulsed with 1 mCi of 3 H-thymidine per well and harvested 4 h later. 3 H-thymidine incorporation into DNA was quantified by liquid scintillation counting in a beta counter (MicroBeta Trilux, Wallac Oy, Turku, Finland).
Apoptosis analysis
Apoptosis induction was evaluated using the annexin V-FITC kit (Beckman Coulter, Miami, FL, USA), according to the manufacturer's instructions and staining was analyzed using EPICS XL4 flow cytometer and Expo 32 software (Beckman Coulter).
Cell cycle analysis
Cells were fixed in 70% ethanol (v/v) in phosphate-buffered saline and incubated at 4 1C overnight. Washed cells were incubated in phosphate-buffered saline containing 40 mg ml
À1
propidium iodide (Sigma) and 100 mg ml À1 DNase-RNase A in ice for at least 10 min. Cell cycle parameters were acquired using LSR flow cytometer and Cell Quest software (Becton Dickinson, Franklin Lakes, NJ, USA). Cell cycle distribution was determined by automatic analysis using the flow cytometry modeling software: ModFit LT with AutoDebris and AutoAggregates. 
Analysis of HLA-G receptor expression
Flow cytometry analysis was performed using anti-ILT-2 and anti-ILT-4 antibodies as previously described. 13 
Statistical analysis
All data are representative of experiments performed at least three times. Significance was assessed by unpaired t-test assuming Po0.05 as significant.
Results and discussion
Following our previous observation of HLA-G expression by erythroid cells, 2 here we analyzed whether HLA-G5 affects erythropoiesis. In the light of its inhibitory role in T-lymphocyte proliferation, 14 we first investigated the effect of HLA-G5 on normal erythroid cell proliferation. For this purpose, we used UT7/EPO cells, 15 the EPOR signal transduction and proliferation of which are similar to those of erythroid progenitors in response to EPO. 16 The UT7/EPO cells were cultured for 24, 48 and 72 h in the presence of 0.0625 IU EPO ml À1 (defined as the EPO concentration required for exponential cell growth) and increasing concentrations of recombinant HLA-G5 (rHLA-G5). Since protein aggregation was previously described as a critical factor for the biological activity of HLA-G5 on immune cells, 11 here we used this protein once aggregated onto microbeads (that is, HLA-G5-beads). We showed that UT7/EPO cell proliferation was significantly reduced by increasing concentrations of HLA-G5-beads (unpaired t-test, Po0.04 for 10 000 HLA-G5-beads per cell; Po0.01 for 20 000 and 30 000 HLA-G5-beads per cell; Po0.003 for 40 000 HLA-G5-beads per cell; n ¼ 3) (Figure 1a ). Inhibition of UT7/EPO cell proliferation ranged from 12.9 ± 6.1% (mean value ± s.e.m.) for 10 000 HLA-G5-beads to 51.6 ± 6.6% for 40 000 HLA-G5-beads. The maximum level of inhibition was already reached after 24 h, pointing out that UT7/EPO erythroid cells rapidly respond to HLA-G5. The highest decrease of cell proliferation was obtained for 40 000 HLA-G5-beads per cell, while the same amount of beads alone did not affect UT7/EPO cell growth (Figure 1b) . Notably, HLA-G blocks erythropoietin receptor signaling C Menier et al inhibition of UT7/EPO proliferation was not associated with increased cell death rate, evaluated using the Trypan blue exclusion method, irrespective of the amount of HLA-G5 and at all time points studied (unpaired t-test, P40.05) (data not shown). We then sought the mechanism responsible for HLA-G5-mediated inhibition of UT7/EPO growth by evaluating both apoptosis and cell cycle distribution. Treatment of UT7/EPO cells during 48 h with 30 000 HLA-G5-beads per cell did not increase annexin V-positive and propidium iodide-negative cells compared to treatment with control beads (mean value ± s.e.m. ¼ 3.4 ± 1.8 vs 3.7 ± 0.9%, respectively, n ¼ 3). Moreover, such HLA-G5 treatment did not change the necrosis rate compared to control beads (11.9 ± 2.9 vs 12.1 ± 4.3%, respectively, n ¼ 3). Similar results were observed after 24 and 72 h treatment (data not shown). These data confirm those obtained using Trypan blue.
We next assessed UT7/EPO cell cycle distribution in response to HLA-G5 by propidium iodide staining. Treatment of UT7/EPO cells for 24 h with 30 000 HLA-G5 beads per cell resulted in an increase in the percentage of cells in G1 phase and a similar decrease in percentage of cells in S phase (Figure 1c) . Taken together, these data show that HLA-G5 lowers proliferation of erythroid cells upon normal EPOR stimulation, in a dosedependent manner, by inducing G1 cell cycle arrest without increasing death rate.
Because JAK2 is the primary tyrosine kinase activated by EPO, we next investigated whether HLA-G5 acts on this protein. We found that JAK2 phosphorylation was decreased in UT-7/EPO cells upon HLA-G5 treatment (Figure 2a) . Such HLA-G5-mediated effect was obtained using either rHLA-G5 (aggregated or not onto microbeads) or naturally produced HLA-G5, that is, immunopurified with microbeads from plasma of liver-kidney transplanted patients who had high HLA-G5 plasma levels.
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Efficiency of HLA-G5 capture by microbeads was checked by western blot analysis, which revealed a band at 37 kDa corresponding to the molecular weight of HLA-G5 (Figure 2a , small inset). In the same experiment, JAK2 protein levels remained similar in UT7/EPO cells treated or not with HLA-G5 (Figure 2a ). These results demonstrate that HLA-G5 affects the phosphorylation of JAK2 without degrading this kinase. Since JAK2 is an upstream protein directly linked to EPOR, its decreased activity by HLA-G5 may cause inhibition of downstream signal-transduction pathways. Therefore, we analyzed whether HLA-G5 affects STAT-5 and STAT-3 activity, as both are activated by JAK2 in response to EPO. 17 As expected, HLA-G5 decreased phosphorylation levels of both STAT-5 and STAT-3 ( Figure 2b ). In conclusion, HLA-G5 prevents EPOR signal transduction by inhibiting JAK2 activity, consequently correlated to reduced erythroid cell proliferation.
Finally, to define whether HLA-G5 acts directly or indirectly on EPOR, UT-7/EPO cells were treated with HLA-G5 for 15 min or 2 h before EPOR activation. The decrease of JAK2 phosphorylation was observed only after 2 h of HLA-G5 treatment (Figure 2c ). This result strongly suggests that HLA-G5 does not interact with EPOR (no effect at 15 min) but rather acts through synthesis of an intermediate signaling protein, presumably a phosphatase. Accordingly, HLA-G5 would bind to a specific receptor present at the cell surface of UT7/EPO erythroid cells. However, we did not observe expression of the known HLA-G inhibitory receptors ILT-2 and ILT-4 on UT7/EPO cells (Figure 2d ), leading us to conclude that HLA-G acts on erythroid cells through an as yet uncharacterized receptor. To date, association of ILT-2 and ILT-4 with HLA-G has been shown to inhibit selectively immune responses and both receptors have not been described on erythroid lineage.
Taking advantage of the above results showing that HLA-G5 downregulates JAK2 phosphorylation upon normal EPOR signal transduction, we then asked whether it could also control constitutive EPOR activation caused by a V617F mutation in JAK2. To answer this question, we worked with the HEL cell line, which carries this homozygous mutation 18 and for which an increased JAK2 phosphorylation has been detected. 7, 19, 20 Treatment of HEL cells with rHLA-G5 reduced the phosphorylation of JAK2 V617F in a dose-dependent manner, as observed with UT7/EPO cells (Figure 3a) . This HLA-G5-mediated decrease of JAK2 V617F phosphorylation was similar to that obtained with the JAK inhibitor I (Figure 3a) , which has been previously described as downmodulating JAK2 V617F phosphorylation in HEL cells. 7, 19, 20 The effect of HLA-G5 on JAK2 phosphorylation was observed at a very low dose, that is, 100 ng ml À1 (4 nM) in comparison with that of the chemical JAK2 inhibitors currently used, that is, 2 mM for JAK inhibitor I (Figure 3a ) and 50 mM for tyrphostin AG490. 21 As seen above with UT7/EPO cells, the diminution of JAK2 V617F phosphorylation was not due to degradation of JAK2 protein (Figure 3a) . Moreover, whether HLA-G5 was aggregated or not onto microbeads, a similar effect on JAK2 activity was observed ( Figure 3) .
To define whether HLA-G5 acts on other targets of EPOR signaling pathways, we used the K562 chronic myeloid leukemia cell line, which does not carry the JAK2 V617F mutation 7, 18 and in which JAK2 is not constitutively phosphorylated in opposition to STAT-5 ( Figure 3b ). 7 Treatment with HLA-G5 did not influence STAT-5 phosphorylation in K562 cells in contrast to HEL cells analyzed in the same experiment (Figure 3b) , as previously described for the JAK inhibitor I. 7, 19, 20 At the same time, a similar reduced phosphorylation of STAT-3 was observed in response to HLA-G5 in HEL cells (Figure 3b) , as described for JAK inhibitor I. 20 To study the possible influence of HLA-G5 on other members of the JAK family, we analyzed the effect of HLA-G5 on NKL cell proliferation. Indeed, NKL cells grow upon stimulation of IL2 receptor the signaling of which is known to be mediated by JAK1 and JAK3 kinases, but not JAK2. 22, 23 The results show that HLA-G5 did not affect NKL cell proliferation under conditions similar to those used for HEL cells, suggesting that HLA-G5 does not affect JAK1 and JAK3 kinase activity (data not shown). Altogether, these results support the direct inhibitory effect of HLA-G5 on JAK2 phosphorylation and allow excluding a direct role of HLA-G5 in STAT-5 signaling protein.
Because HEL cells carry JAK2 V617F mutation, they proliferate in the absence of EPO. 7 Whether HLA-G5 also affects EPO-independent growth of such erythroid cells was then investigated. Analysis of HEL proliferation was performed after 24, 48 and 72 h following treatment with HLA-G5 (30 000 beads per cell) or JAK inhibitor I (500 nM). 7 We found that HLA-G5 inhibits HEL cell proliferation (35.7±7.7%, mean % of inhibition ± s.e.m., n ¼ 6) (Figure 4a) . Similar results were obtained with JAK inhibitor I (48.8 ± 4.3%) (Figure 4a ) as previously described. 7, 19 As we observed for UT7/EPO cells, JAK inhibitor I-or HLA-G5-bead-mediated inhibition of HEL proliferation was maximum 24 h after treatment and remained stable over time (n ¼ 6, P40.05). There was no significant difference in HEL proliferation inhibition between HLA-G5-beads or JAK inhibitor I treatment at each time point analyzed (n ¼ 6, P40.05). These results show that HLA-G5 is indeed capable of reducing EPO-independent erythroid cell proliferation. Of note, neither ILT-2 nor ILT-4 inhibitory receptor is expressed by HEL cells (Figure 2d) .
We asked whether the combination of JAK inhibitor I and HLA-G5 induces more pronounced effects than either agent alone. The results show that HLA-G5 together with JAK inhibitor I has an additive effect in inhibiting HEL cell growth compared to each agent alone at 24 h (Po0.01 for HLA-G5 and Po0.05 for JAK inhibitor I), and also compared to HLA-G5 alone at 48 and 72 h (Po0.05) (Figure 4a) . Finally, K562 cell proliferation was analyzed in the same experiments showing that both JAK inhibitor I and HLA-G5 have no effect on their proliferation (data not shown), supporting the above-mentioned result where HLA-G5 has no effect on STAT-5 phosphorylation in this cell line.
Next, since the mechanisms involved in HEL growth inhibition by JAK inhibitor I were found to be mainly G1 cell cycle arrest and to a lesser extent apoptosis entry, 7, 19, 20 we investigated both mechanisms in HEL cells treated with HLA-G5. First, we analyzed cell cycle distribution of HEL cells after 24 h treatment with 30 000 HLA-G5-beads or 1 mM JAK inhibitor I. As we observed for UT7/EPO cells, HLA-G5 induced an increase in the percentage of HEL cells in G1 phase (Figure 4b) . A similar enhancement (about 10%) was seen using JAK inhibitor I (Figure 4b) . Second, we evaluated whether a 48 h HLA-G5 treatment induced HEL cell apoptosis. Whether treated with beads alone or HLA-G5-beads, the proportion of apoptotic cells remained unchanged (1.3 ± 0.3 and 0.9 ± 0.3%, n ¼ 3), and (c) HEL cell cycle distribution upon these three treatments was evaluated as described in Figure 1c .
HLA-G blocks erythropoietin receptor signaling C Menier et al only a minor increase was observed in the proportion of necrotic cells (7.3±0.8 and 9.7±1.8%, n ¼ 3). Related results were obtained when HEL cells were treated with 1 mM JAK inhibitor I in the same set of experiments. Actually, 2.3±0.6% of the total population treated with the JAK inhibitor I showed signs of apoptosis against 1.7±0.4% for untreated cells (n ¼ 3). The percentage of necrotic cells upon JAK inhibitor I treatment was 9.7±1.8% against 7.2±0.1% for untreated cells (n ¼ 3). One representative example of this set of experiments is shown in Figure 4c . These results contrast with those in the literature, which described induction of HEL apoptosis with the JAK inhibitor I. 7, 19, 20 Nevertheless, in our hands, JAK inhibitor I did not cause apoptosis of HEL cells. Our HEL cell line may have characteristics different from those used in previous reports, such as a small number of JAK2 copies. Thus, we cannot conclude whether HLA-G5 and JAK inhibitor I have similar mechanisms of action. In summary, we found that HLA-G5 is able to downregulate both normal and constitutive EPOR signaling leading to counteraction of EPO-dependent and EPO-independent erythroid cell line proliferation, respectively. One of the mechanisms involved in HLA-G5 growth inhibition is a stop in G1-phase cell cycle and not apoptosis induction. HLA-G5 effects start from the beginning of the EPOR signaling cascade by reducing the phosphorylation of JAK2 and JAK2 V617F without degrading this kinase. As a consequence, HLA-G5 also decreases EPOR downstream STAT-5 and STAT-3 activities.
Finally, the involvement of JAK2 in erythrocyte production has recently been highlighted by the role of activating JAK2 V617F mutation in PV pathogenesis. [6] [7] [8] [9] Actually, PV disorder is characterized by an overproduction of erythroid cells in peripheral blood, which is correlated with enhanced JAK2 V617F activity. We examined HLA-G5 effects on the proliferation of erythroid progenitor cells from PV patients since EPOindependent erythroid colonies derived from PV progenitors carry the JAK2 V617F mutation. 5 We found that EPOindependent erythroid colony growth was inhibited by rHLA-G5 (61.3±13.1% inhibition) in six (patients nos. 1, 3, 4-7) out of seven PV patients analyzed (Figure 5a ). We also analyzed whether HLA-G5 also acts on EPO-dependent erythroid cell growth. Recombinant HLA-G5, used at 100 ng ml
À1
, did not affect the growth of such erythroid colonies from PV patients no. 1-3 cultured in the presence of 3 IU EPO ml À1 for patient no. 1 and 0.5 IU EPO ml À1 for patients nos. 2 and 3 (data not shown). However, using a lower dose of EPO (0.1 IU ml À1 ), HLA-G5 inhibited the EPO-dependent growth of erythroid colonies from patient nos. 7 and 8 by 60 and 73%, respectively (Figure 5b) . Thus, HLA-G5-mediated inhibition of EPO-dependent growth of erythroid colonies appears to be dependent on the EPO dose: while at low doses, HLA-G5 exerts its inhibitory effect on erythroid growth, at higher doses, HLA-G5-mediated inhibition is no longer efficient and may be counterbalanced by EPO stimulation. Since we demonstrated in our experiments using UT7/EPO and HEL erythroid cell lines that HLA-G5 was able to directly inhibit their proliferation, we propose that HLA-G5 acts at least directly on the EPO-independent erythroid clones from PV patients. However, since PV erythroid progenitor cells were not highly purified, we cannot totally rule out HLA-G5 effect on auxiliary cells inducing the release of factor(s) that may influence EPO-independent erythroid colony growth.
Altogether, HLA-G5 represents a novel parameter to be considered in future approaches aimed at treating PV, one of the main myeloproliferative disorders for which the JAK2 V617F mutation is present at high frequency at diagnosis. 24 Indeed, HLA-G may allow reduction of increased erythroid cell proliferation, which constitutes a critical clinical manifestation of PV. 25 Up to now, conventional treatments are not efficient since they do not selectively act on the clones carrying the JAK2 V617F mutation. However, a high molecular response in PV patients treated with pegylated IFN-a-2a has recently been shown. 26 HLA-G expression is known to be upregulated upon IFN-a treatment in cancer patients. Indeed, melanoma patients who have undergone immunotherapy with IFN-a showed increased HLA-G5 serum concentrations. Considering the tumor stage, tumor burden and therapy modalities, the multivariate analysis of 190 melanoma patients revealed that treatment with IFN-a was the only impact factor for elevated serum HLA-G5. 27, 28 Whether therapeutic benefit after IFN-a-2a treatment occurs by boosting HLA-G5 expression in PV patients would deserve particular attention in future clinical investigations.
Conclusion
In addition to its role in suppressing immune response, HLA-G is defined here for the first time as a novel negative regulatory mechanism controlling erythropoiesis. We also show that HLA-G has the same inhibitory effects on JAK2 V617F-induced EPOR signaling and prevents the EPO-independent growth of erythroid progenitors from PV patients. Interestingly, we found that HLA-G5 and the JAK inhibitor I effects are additive. Therefore, our present results warrant additional studies to explore the translational value of our observations in terms of treatment in the JAK2 V617F-positive myeloproliferative disorders.
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